Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
Search or
𝛼
SK
SIGN UP
SIGN IN
ENTITY
Centene (CNC UN)
Watchlist
1
Analysis
Health Care
•
United States
Centene Corporation provides multi-line healthcare solutions to individuals across all states and internationally. Centene's specialty services include medicaid and medicare health plans, treatment compliance, and nurse triage.
more
Watchlist
All
Insights
Primers
New
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
27 Oct 2016 13:36
Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector:Mid-Week Update (October 27)
SummaryWe discuss our portfolio companies Acadia Pharmaceuticals Inc (ACAD US), Portola Pharmaceuticals Inc (PTLA US), Dynavax Technologies Corp...
Dr. Bhavneesh Sharma, MD, MBA
341 Views
Share
bullish
•
Thematic (Sector/Industry)
•
25 Oct 2016 10:24
Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector: October 24 (Monday)
Summary: We discuss Atyr Pharma Inc (LIFE US), DBV Technologies SA (DBV FP), Advaxis Inc (ADXS US), Global Blood Therapeutics Inc (GBT US),...
Dr. Bhavneesh Sharma, MD, MBA
597 Views
Share
bullish
•
Thematic (Sector/Industry)
•
20 Oct 2016 11:25
Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector: Mid-Week Update
Galapagos NV (GLPG NA) seems to have got some investor attention after the successful results of Celgene Corp (CELG US) anti-inflammatory product...
Dr. Bhavneesh Sharma, MD, MBA
504 Views
Share
bullish
•
Thematic (Sector/Industry)
•
19 Oct 2016 11:19
Recap of Key U.S. Biotechnology and Pharmaceutical Sector Events: October 17
Celgene (NASDAQ: CELG) announced successful phase 1b data of its antisense therapy GED-0301 in the treatment of Crohn's disease (48% remission rate...
Dr. Bhavneesh Sharma, MD, MBA
316 Views
Share
bullish
•
Thematic (Sector/Industry)
•
07 Jul 2016 10:21
No Pain, Potential for Lots of Gain for Pfizer, Lilly, and Regeneron
The history of pain drugs that target nerve growth factor has been a roller-coaster ride for drug developers and investors. In 2010, expectations...
Morningstar, Inc.
255 Views
Share
First
Previous
1
2
3
4
5
6
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.59.9
x